Last edition
News about "Eli Lilly and Company "
Eli Lilly's Foundayo and Lower-Dose Zepbound Maintain Weight Loss in Late-Phase Trials
Eli Lilly and Company reports late-stage trial data showing Foundayo and lower-dose Zepbound helped patients maintain significant long-term weight loss after switching from higher-dose incretin therapies.
Eli Lilly And Company | 13/05/2026 | By News Bureau
Eli Lilly and Company's Omvoh Shows 4-Year Disease Clearance in Ulcerative Colitis
Eli Lilly and Company’s Omvoh (mirikizumab-mrkz), the first IL-23p19 inhibitor, shows durable disease clearance in ulcerative colitis, with more than 60 percent of patients maintaining remission through 4 years in the LUCENT-3 study.
Eli Lilly And Company | 06/05/2026 | By News Bureau
Eli Lilly and Company to Acquire Ajax Therapeutics to Expand Blood Cancer Pipeline
Eli Lilly and Company to acquire Ajax Therapeutics, advancing its blood cancer pipeline with AJ1-11095, a Phase 1 JAK2 inhibitor targeting myelofibrosis and polycythemia vera, with potential for improved disease control.
Eli Lilly And Company | 28/04/2026 | By News Bureau
Amazon Pharmacy to Deliver Foundayo Same-Day, Expanding Access to Eli Lilly's New GLP-1 Pill
Amazon Pharmacy now offers Eli Lilly’s GLP-1 pill Foundayo with real-time availability, transparent pricing from USD 1/day with insurance, USD 5/day cash, and automatic manufacturer-sponsored coupons—soon via in-office kiosks within minutes.
Eli Lilly And Company | 09/04/2026 | By News Bureau | 143
Fauna Bio Announces Target Designation Milestone in Obesity Discovery Collaboration
Fauna Bio has achieved a target designation milestone in its obesity discovery collaboration, advancing a novel target identified through its Convergence AI platform.
Eli Lilly And Company | 20/03/2026 | By News Bureau
Zuellig Pharma has acquired rights to Cialis from Eli Lilly and Company in Hong Kong, Macau and South Korea, expanding its ownership of the men’s health drug across 11 Asian markets.
Eli Lilly And Company | 16/03/2026 | By News Bureau | 178
Lilly Positions India as Global Manufacturing Hub Amid Mounjaro Demand
Eli Lilly and Company is moving to position India as a strategic global manufacturing and export hub, supported by strong demand for its blockbuster diabetes and obesity therapy Mounjaro. A senior executive said the company is advancing plans to integrate India more deeply into its worldwide supply chain through contract manufacturing partnerships.
Eli Lilly And Company | 18/02/2026 | By Darshana | 250
Lilly's Retevmo Shows Significant Benefit in Early-Stage RET+ Lung Cancer in Phase III Trial
LIBRETTO-432 study demonstrates statistically significant improvement in event-free survival as adjuvant therapy for stage II–IIIA RET fusion-positive NSCLC.
Eli Lilly And Company | 17/02/2026 | By News Bureau | 186
Innovent Biologics and Eli Lilly Forge Strategic Collaboration in Oncology and Immunology
Innovent Biologics will receive USD 350 million upfront and up to USD 8.5 billion in milestones under a new global development pact, with Lilly securing ex-Greater China rights to novel oncology and immunology programmes.
Eli Lilly And Company | 10/02/2026 | By News Bureau | 112
Lilly’s acquisition of Orna Therapeutics aims to accelerate development of in vivo CAR-T therapies powered by engineered circular RNA and advanced lipid nanoparticle delivery platforms.
Eli Lilly And Company | 10/02/2026 | By News Bureau | 183
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy